CABTREO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CABTREO (CABTREO).
Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. Tretinoin is a retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression to normalize follicular keratinization and reduce microcomedone formation. Benzoyl peroxide is a keratolytic and oxidizing agent that reduces Propionibacterium acnes counts and has comedolytic activity.
| Metabolism | Clindamycin phosphate is hydrolyzed to clindamycin, which is metabolized primarily by the liver via CYP3A4 and to a lesser extent by other CYP enzymes. Tretinoin undergoes oxidative metabolism via CYP450 enzymes. Benzoyl peroxide is metabolized to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted in urine. |
| Excretion | Following topical application of CABTREO (clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%) gel, systemic absorption of clindamycin is minimal. Clindamycin is primarily eliminated via renal excretion (approximately 10% unchanged and metabolites); biliary/fecal excretion accounts for the remainder. Adapalene is primarily eliminated via biliary/fecal excretion; renal excretion is negligible. Benzoyl peroxide is metabolized to benzoic acid, which is conjugated and excreted renally. |
| Half-life | The terminal elimination half-life of clindamycin after topical application is approximately 2-3 hours in the systemic circulation, but due to prolonged residence in the skin, clinical effects may persist. Adapalene has a terminal half-life of approximately 7-12 hours after topical application; its retention in the skin contributes to once-daily dosing. For benzoyl peroxide, the half-life of its metabolite benzoic acid is about 1-2 hours. |
| Protein binding | Clindamycin is approximately 60-95% bound to plasma proteins (primarily albumin). Adapalene is highly protein-bound (>99%), mainly to albumin and lipoproteins. Benzoyl peroxide is not protein-bound; its metabolite benzoic acid is approximately 40% protein-bound. |
| Volume of Distribution | For clindamycin, the apparent volume of distribution is approximately 0.6-1.2 L/kg after systemic absorption, but due to minimal absorption from topical application, the effective Vd is not clinically defined. Adapalene has a large Vd (>100 L) due to extensive tissue distribution, but after topical dosing, systemic exposure is low. Benzoyl peroxide's metabolite benzoic acid has a Vd of about 0.2-0.3 L/kg. |
| Bioavailability | Topical bioavailability of clindamycin from CABTREO gel is approximately 1-5% of the applied dose. Adapalene bioavailability after topical application is less than 1%. Benzoyl peroxide is absorbed minimally; systemic exposure to its metabolite benzoic acid is low but quantifiable. |
| Onset of Action | Clinical onset of action (reduction in acne lesions) is typically observed within 2-4 weeks of once-daily topical application. This is consistent with the onset of adapalene's retinoid effects and benzoyl peroxide's antibacterial action. |
| Duration of Action | Duration of action supports once-daily dosing for sustained efficacy over 12 weeks of treatment. The combination provides continuous antimicrobial and retinoid activity; effects may persist for several days after discontinuation due to skin retention. |
Topical administration, apply a pea-sized amount to the face once daily in the evening.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. Use with caution in Class A. |
| Pediatric use | Approved for patients aged 12 years and older. Apply a pea-sized amount to affected areas once daily in the evening. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to potential increased skin sensitivity and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CABTREO (CABTREO).
| Breastfeeding | No data on CABTREO in breast milk. Clindamycin is excreted in human milk; topical use likely minimal. Adapalene and benzoyl peroxide are minimally absorbed. M/P ratio not available. Use with caution; avoid application to breast area to prevent infant exposure. |
| Teratogenic Risk | CABTREO contains clindamycin, adapalene, and benzoyl peroxide. Clindamycin is not teratogenic in animal studies, but systemic absorption minimal. Adapalene is a retinoid-like compound; topical application in pregnant women has not shown increased risk of malformations, but animal studies with oral adapalene show teratogenicity. Benzoyl peroxide is considered low risk. Overall, based on limited human data, risk of major birth defects is low but cannot exclude; avoid use in first trimester unless clearly needed. |
■ FDA Black Box Warning
Not applicable. There is no FDA black box warning for CABTREO.
| Serious Effects |
["Hypersensitivity to clindamycin, tretinoin, benzoyl peroxide, or any component of the formulation.","History of pseudomembranous colitis or antibiotic-associated colitis.","Concomitant use with other retinoids (oral or topical) or photosensitizing agents.","Pre-existing eczematous or seborrheic dermatitis (due to irritation potential)."]
| Precautions | ["Colitis: Use of clindamycin may result in Clostridium difficile-associated diarrhea (CDAD).","Photosensitivity: Tretinoin increases sensitivity to sunlight; use sunscreen and avoid sunlamps.","Skin irritation: Local reactions such as erythema, peeling, burning, and pruritus may occur.","Pregnancy: Tretinoin is teratogenic in animals; consider risks in pregnant women (Pregnancy Category C).","Pediatric use: Safety and efficacy in patients under 12 years have not been established."] |
| Food/Dietary | No clinically significant food interactions with topical CABTREO. No dietary restrictions required. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical use; pregnancy testing not mandated. Routine prenatal care. |
| Fertility Effects | No known effects on fertility from topical application; systemic levels low. |
| Clinical Pearls | CABTREO is a fixed-dose combination of clindamycin 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% for topical treatment of acne vulgaris. Apply a pea-sized amount to the entire face once daily in the evening. Avoid concomitant use with other topical products containing benzoyl peroxide or retinoids to prevent excessive irritation. Use skin barrier repair creams to mitigate xerosis and peeling. Do not apply to broken or eczematous skin. Monitor for signs of bacterial overgrowth or Clostridium difficile-associated diarrhea, though systemic absorption is minimal. |
| Patient Advice | Use only as directed: apply a pea-sized amount to the entire face once daily in the evening. · Wash hands after application and avoid contact with eyes, mouth, and mucous membranes. · May cause skin dryness, peeling, or redness; use a gentle moisturizer and sunscreen daily. · Do not use with other acne treatments containing benzoyl peroxide, retinoids, or antibiotics unless advised by your healthcare provider. · Reduce frequency of application if excessive irritation occurs; consult your doctor if severe. · Avoid exposure to UV light and use broad-spectrum sunscreen of SPF 30 or higher. · Stop use and seek medical attention if signs of allergic reaction (hives, difficulty breathing, swelling) or severe local reaction occur. |